NASDAQ: ONCBeone Medicines Ltd Stock
$268.17-2.63 (-0.97%)
Updated Jun 9, 2026
ONC Price
$268.17
Fair Value Price
N/A
Market Cap
$29.84B
52 Week Low
$239.25
52 Week High
$385.22
P/E
744.92x
P/B
6.27x
P/S
5.74x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.74B
Earnings
$513.02M
Gross Margin
88.3%
Operating Margin
13.11%
Profit Margin
8.9%
Debt to Equity
0.8
Operating Cash Flow
$1B
Beta
0.98
Next Earnings
Aug 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ONC Overview
BeOne Medicines Ltd. (ONC), initially founded in 2010 as BeiGene, stands as a prominent global oncology enterprise committed to identifying, advancing, and bringing to market cutting-edge cancer treatments. The company underwent a significant transformation, rebranding as BeOne in late 2024 and subsequently relocating its headquarters from Cambridge, Massachusetts, to Basel, Switzerland, in 2025. With a vast operational footprint extending across more than 45 countries and six continents, BeOne has firmly established itself as a leader in both immuno-oncology and targeted therapy solutions. Its strong product lineup includes key assets such as Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved worldwide for a variety of cancer types, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that has surpassed $1.3 billion in annual revenue and is approved in major regions like the U.S., Europe, and China. BeOne's strategic foundation combines proprietary research and development efforts with the integration of compounds obtained through external alliances, thereby fueling a comprehensive pipeline addressing both blood cancers and solid tumors.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ONC's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ONC
Ranked#6 of 460
Ranked#6 of 460
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $229.19 | A | |
| $52.99 | A | |
| $15.78 | A |
Be the first to know about important ONC news, forecast changes, insider trades & much more!
ONC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ONC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ONC is poor value based on its earnings relative to its share price (744.92x), compared to the US market average (14.33x)
P/E vs Market Valuation
ONC is poor value based on its earnings relative to its share price (744.92x), compared to the US Biotechnology industry average (17.38x)
P/E vs Industry Valuation
ONC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more ONC due diligence checks available for Premium users.
Valuation
ONC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
744.92x
Industry
17.38x
Market
14.33x
ONC is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ONC is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
ONC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.27x
Industry
4.77x
ONC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ONC's financial health
Profit margin
Revenue
$1.5B
Net Income
$227.4M
Profit Margin
15%
ONC's Earnings (EBIT) of $752.14M... subscribe to Premium to read more.
Interest Coverage Financials
ONC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.6B
Liabilities
$3.8B
Debt to equity
0.8
ONC's short-term assets ($6.60B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ONC's short-term assets ($6.60B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ONC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ONC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$201.3M
Investing
-$45.5M
Financing
$68.6M
ONC's operating cash flow ($1.28B)... subscribe to Premium to read more.
Debt Coverage Financials
ONC vs Biotech Stocks
Beone Medicines Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.